Why statins suck: the trial numbers, the label and what your cells are missing

By The Holistic Hub Editorial CollectiveNov 2, 2026(updated Nov 2, 2026)

Sources listed

Statins are the most prescribed drug in the United States and in England, and in their own trials they postponed death by a median of 3.2 days.[1]DOI The ad says 29 percent fewer heart attacks. In absolute terms that is 1.3 fewer heart attacks per 100 people treated.[2]DOI The line for who should take one kept moving, the label lists more than the blinded trials confirm, and the labs a statin is meant to fix sit downstream of nutrients your cells may be missing, which almost nobody is trained to measure. This post goes through each of those, with the study behind every number. It is not advice to stop a prescription. It is the information that belongs in the conversation about one.

The most prescribed drug in the US and in England

In 2024 atorvastatin was the most prescribed drug in the United States by prescription count, at 115.7 million, with rosuvastatin ninth at 53.7 million (ClinCalc DrugStats). In England it was the most dispensed drug in 2025/26, at 78 million items (NHS Business Services Authority). In Australia the two most-subsidized drugs by prescriptions in 2024-25 were rosuvastatin and atorvastatin (PBS). You will hear that statins are banned in Europe. England alone dispensed 78 million items of a single statin in one year. A drug this widely taken deserves a close look at what it does for the average person who takes it.

In their own trials: 3.2 days

In a systematic review of 11 randomized statin trials lasting 2 to 6 years, the median postponement of death was 3.2 days in people without prior heart disease and 4.1 days in people with it.[1]DOI That is an average within the trial period, not a lifetime gain, and an average of days can hide a minority who gain years. The Cochrane review of 14 primary-prevention trials found that statins reduced all-cause mortality, cardiovascular events and revascularization, and added that selective outcome reporting warranted caution in low-risk people.[3]DOI Both findings are on the record. What the headline never answers is how much, for whom, and measured how.

Relative risk is the ad. Absolute risk is what you are buying.

Across 21 large randomized statin trials, the absolute risk reductions were 0.8 percentage points for all-cause death, 1.3 for heart attack and 0.4 for stroke, and the relative reductions were 9, 29 and 14 percent. The authors noted that significant heterogeneity reduced the certainty of the evidence and that absolute reductions belong in the conversation with each patient.[2]DOI Both sets of numbers are true. The 29 percent is the one in the advertising, and it is 1.3 people in 100. Cardiologist Dr. Aseem Malhotra laid it out on the Joe Rogan Experience: over five years after a heart attack, "best case scenario, your benefit of a statin is 1 in 83 for saving your life," and when Rogan asked how much life that adds, the answer was "Just over four days" (transcript). The trial analysis above found 4.1 days for people with prior heart disease.

The goalposts moved, with statin money in the room

The dated history is in the goalposts timeline. The first statin was approved in August 1987 (FDA), the first national cholesterol guideline followed in January 1988 (NCEP ATP I), and in 2004 eight of the nine authors of the guideline update had undisclosed financial ties to makers of cholesterol-lowering drugs, as the BMJ reported in 2004 (the report is linked in the timeline). The line for who qualifies has kept widening. One analysis projected that the 2013 guideline would raise statin eligibility among US adults aged 40 to 75 from 37.5 percent to 48.6 percent,[4]PubMed and a 2026 analysis found the newest guideline expands primary-prevention eligibility to 56.6 percent of US adults, mostly younger, lower-risk people with a 10-year risk of 3.1 percent.[5]PubMed Who paid for the evidence is part of the picture too: in head-to-head statin trials, the industry-funded ones favored the sponsor's drug at 20 to 35 times higher odds than adequately blinded trials.[6]PubMed

Your brain runs on fat

The central nervous system holds about 23 percent of the body's sterol, and brain cholesterol comes from local synthesis rather than from the blood.[7]PubMed Myelin, the insulation around nerves, is uniquely enriched in cholesterol,[8]PubMed and cholesterol is essential for cell membrane physiology throughout the body.[9]PubMed Too little cholesterol impairs cell membrane integrity, neurotransmission and immune function, according to one narrative review.[10]PubMed The first food a human brain is built on is mother's milk. Human milk contains cholesterol,[11]PubMed has the lowest share of saturated fat among the mammal milks tested,[12]PubMed and carries long-chain omega-3 and omega-6 fats, the kind (DHA and arachidonic acid) that are added to infant formula: breastfed infants, who get them naturally, scored higher on IQ tests than infants fed formula lacking them in one review.[13]PubMed[14]DOI

The side-effect list: what the label reports, what blinded trials confirm

The FDA label for atorvastatin, the most prescribed statin, lists its most common adverse reactions as nasopharyngitis, arthralgia, diarrhea, pain in extremity and urinary tract infection, and it warns about muscle breakdown (rhabdomyolysis), immune-mediated necrotizing myopathy, liver enzyme increases, higher HbA1c and fasting glucose, and rare reports of memory loss and confusion (FDA label, 2024). In the label's own table of placebo-controlled trials, each of those five common reactions ran within half a percentage point of the placebo rate; arthralgia was 6.9 percent against 6.5 percent. That gap between a long list and a short confirmed list is the finding. A 2026 meta-analysis of double-blind statin trials confirmed abnormal liver function tests, urinary changes and edema as causally associated, and found that most label-listed effects lacked evidence.[15]PubMed Muscle: an individual-participant meta-analysis of large blinded trials found a small excess of muscle pain in year one, with only 1 in 15 muscle-pain reports attributable to the statin,[16]DOI yet in clinical practice 15 to 20 percent of patients report muscle and joint effects against 1 to 5 percent in trials,[17]PubMed and in randomized rechallenge trials of people who had stopped a statin, intolerance was more common on a statin than on placebo (36 percent against 26 percent) though muscle symptom scores did not differ significantly.[18]PubMed Blood sugar is where dedicated analyses of blinded trials do find a signal beyond that short list: new-onset diabetes rose by 10 to 36 percent, dose-dependently, mostly in people already near the diagnostic threshold.[19]PubMed Liver: the label reports persistent transaminase increases above three times the upper limit in about 0.7 percent of patients in its trials, and a systematic review of secondary-prevention trials found transaminase elevations highest with atorvastatin.[20]PubMed Memory: a 2026 systematic review found cholesterol-lowering drugs did not increase neurocognitive events or impair cognitive function.[21]PubMed

A statin is not a cholesterol-only switch

Statins block HMG-CoA reductase, an early step on the mevalonate pathway, and that pathway also makes other molecules, including coenzyme Q10 and dolichol.[22]PubMed In a meta-analysis of 12 randomized trials with 1,776 participants, statin treatment reduced circulating coenzyme Q10 regardless of statin type, intensity or treatment duration,[23]PubMed and in 67 patients after a heart attack a newly started statin lowered plasma coenzyme Q10 by 43 percent.[24]PubMed A review examined whether statins also disrupt mitochondria, a mechanism explored for muscle pain, diabetes risk and cognitive effects.[25]PubMed Whether the lower level causes symptoms is not settled: that 43 percent drop did not correlate with the muscle-injury marker measured.[24]PubMed Putting it back has mixed results. A randomized crossover trial funded by the US National Institutes of Health found that 600 mg a day of ubiquinol did not reduce statin muscle pain against placebo,[26]PubMed while a 2025 meta-analysis of seven randomized trials, funded by the Society for Applied Vitamin Research, found a modest reduction in muscle pain with three of the seven trials showing no change.[27]DOI The liver is where the drug acts, and it responds: statins work through inhibiting cholesterol synthesis and upregulating hepatic LDL receptors.[28]Source

There is no good and bad cholesterol

Cholesterol is carried. HDL protects against coronary heart disease by driving reverse cholesterol transport, removing excess cholesterol from tissues for excretion through the liver and bile.[29]PubMed LDL delivers: steroid-making tissues take in cholesterol through LDL-receptor uptake as well as from HDL.[30]PubMed The harm sits in the particle that has been oxidized in the vessel wall: one review argues that atherosclerosis is driven by oxidized LDL, which macrophages take up to form foam cells, rather than by native LDL,[31]DOI and in 22 adults six months of beta-carotene, vitamin C and vitamin E lengthened the time before LDL began to oxidize, though total oxidation was unchanged.[32]PubMed Particle number counts too: in 3,066 middle-aged adults followed for a median of 15 years, LDL particle number was more strongly associated with first cardiovascular events than LDL cholesterol was.[33]DOI The layer that keeps cholesterol and cells off the vessel wall, the glycocalyx, breaks down in high cholesterol, atherosclerosis and obesity.[34]PubMed The studies behind that run through the cardiac blog and the cardiac stack.

Your cardiac labs are not off because you have a statin deficiency

Nobody's cells are missing a statin. What the numbers on a cardiac report sit downstream of is what the vessel wall and the kidney run on, and a few essential nutrients carry much of it. Potassium: pooling 32 randomized trials, higher potassium intake produced a dose-dependent reduction in blood pressure,[35]Source and across 104 studies of 2,755,719 participants higher dietary potassium was associated with lower odds of chronic kidney disease.[36]PubMed Almost nobody reaches the target: in NHANES 2009-2010 fewer than 1 percent of US females reached the 4,700 mg Adequate Intake then in force,[37]PubMed and in 2017-2018 only about a quarter of adults exceeded today's lower one.[38]PubMed Potassium can also run low inside the cell while the blood number looks normal.[39]PubMed Magnesium: pooling 34 trials, supplementation at about 370 mg a day was associated with modest reductions in blood pressure.[40]PubMed Vitamin E: in 26,282 US adults, intake fell below the estimated average requirement in 84 percent.[41]DOI Vitamin K2: a two-year randomized placebo-controlled trial found menaquinone-7 at 360 mcg a day associated with roughly 29 percent less progression of coronary artery calcification in people with mild coronary disease.[42]Source The food lost minerals too: USDA records for 43 garden crops show declines in several minerals between 1950 and 1999.[43]PubMed None of these is a cure and none replaces a prescription. They are the inputs, and a routine lab report does not show them.

It is not your doctor's fault. It is the training.

Your doctor did not lie to you. Your doctor was trained, and nutrition was a sliver of the training. A national survey found that U.S. medical students received an average of 19.6 hours of nutrition instruction over their entire medical career, with only 27 percent meeting the recommended 25-hour minimum.[44]DOI A later analysis found that 71 percent of U.S. medical schools failed to meet the 25 hours, averaging 14.3 hours in the preclinical years.[45]DOI In a survey of physicians, 95 percent affirmed that nutrition is part of their role and only 26 percent felt confident in their knowledge.[46]PubMed In national office-visit data for 2013-2014, hyperlipidemia drug prescribing stayed flat at about 55 percent while diet and exercise counseling fell sharply after 2005.[47]PubMed The system works as designed: a number goes in and a prescription comes out, and measuring what the cells are missing is not part of the visit. Nobody is paid to measure it, and that is the argument. The training is the fact.

Shouldn't your lab results tell you what foods to eat?

They should. That is what the Lab Atlas is: international research, from all over the world, on which foods move the needle on your labs. It is education, not medical advice, because this is not what medical school teaches. You will be able to order your own labs, track your results, share them with your provider, own your health data and learn how to use food as medicine. The Lab Atlas is coming soon, and the waitlist is open.

Join the Lab Atlas waitlist (coming soon)

What to do with a number

None of this is an instruction to stop a prescription, and nobody should stop one on their own. It is the list of questions that belongs in the visit: what is the absolute benefit for me, who set the threshold, who paid for the trials, what does the label warn about that I should watch for, and what are my cells getting from food. Then measure what the visit does not. The research behind every number is in the studies library. Education only, not medical advice.

Key Takeaways

Atorvastatin is the most prescribed drug in the US by prescription count (115.7 million in 2024) and in England (78 million items in 2025/26).
In 11 randomized statin trials the median postponement of death was 3.2 days without prior heart disease and 4.1 days with it; across 21 trials the absolute reductions were 0.8, 1.3 and 0.4 percentage points for death, heart attack and stroke, against relative reductions of 9, 29 and 14 percent.
The FDA label lists more than blinded trials confirm: a 2026 meta-analysis confirmed abnormal liver tests, urinary changes and edema and found most label-listed effects lacked evidence; a small excess of muscle pain appears in year one, and new-onset diabetes rose 10 to 36 percent, mostly near the diagnostic threshold.
Statins block an early step on the mevalonate pathway that also makes coenzyme Q10; they lowered circulating coenzyme Q10 across 12 randomized trials, and whether that causes symptoms is not settled.
Cholesterol is carried, not good or bad: HDL collects, LDL delivers, the harm sits in the oxidized particle, and the brain holds about 23 percent of the body's sterol.
U.S. medical students averaged 19.6 hours of nutrition instruction in the whole of medical training, while potassium, magnesium, vitamin E and vitamin K2 each have human studies behind the numbers on a cardiac report.

Sources

Explore the full evidence in the library

Primary documents and informed-consent resources

Open the original documents. Advocacy resources are included for perspective and are not substitutes for the primary record.

1.ClinCalc DrugStats: The Top 300 Drugs of 2024Atorvastatin ranked 1 with 115,678,209 prescriptions; rosuvastatin ranked 9 with 53,688,649.
2.NHS Business Services Authority, Prescription Cost Analysis England 2025/26Atorvastatin was the most dispensed chemical substance, with 78 million items. Published 4 June 2026.
3.PBS Expenditure and Prescriptions Report 2024-25, Table 5(b)Rosuvastatin 9,479,981 and atorvastatin 7,483,831 subsidised prescriptions, the top two drugs by prescriptions.
4.FDA label, atorvastatin (revised 4/2024)Sections 5.1 to 5.4, 6.1 (adverse reactions table, 17 placebo-controlled trials) and 6.2 (postmarketing reports).
5.Dr. Aseem Malhotra, Joe Rogan Experience #1979 (April 29, 2023), transcriptThe 1-in-83 and 'Just over four days' lines, five years after a heart attack.
6.Byrne et al., JAMA Intern Med 2022: absolute and relative effects of statins in 21 trials DOIAbsolute 0.8% / 1.3% / 0.4%; relative 9% / 29% / 14%; significant heterogeneity reduces certainty.
7.FDA Drugs@FDA: lovastatin (Mevacor), NDA 019643Approved August 31, 1987, the first statin.
8.NCEP Adult Treatment Panel I, Arch Intern Med, January 1988 PubMedTotal cholesterol under 200 mg/dL named desirable.

Cholesterol, Statins, and the Numbers That Changed Cardiac Is the Number One Killer. Here Is What the Evidence Says to Do. How to Read Cardiovascular Labs The cardiac stack: the minimum six

Want the next one of these?

The Signal is one email when there is something genuinely worth your attention -- written the way this post is, in plain language, with the studies behind it. No noise, no selling your address, and nothing to buy.

The Signal, and nothing else -- no fixed schedule, only when there is something worth sending. We never sell or share your address, and you can unsubscribe in one click any time.

All Posts

Statins are the most prescribed drug in the US and England, and in 11 randomized trials the median postponement of death was 3.2 days without prior heart disease and 4.1 days with it. Across 21 trials the absolute reductions were 0.8, 1.3 and 0.4 percentage points for death, heart attack and stroke. The FDA label lists more adverse effects than double-blind trials confirmed, and the lab numbers a statin chases sit downstream of nutrients most adults are short of.

FAQ

Do statins really prevent heart attacks and deaths?

Across 21 large randomized trials, statins reduced all-cause death by 0.8 percentage points, heart attack by 1.3 and stroke by 0.4, which are relative reductions of 9, 29 and 14 percent. In 11 trials lasting 2 to 6 years, the median postponement of death was 3.2 days without prior heart disease and 4.1 days with it. The Cochrane review of 14 primary-prevention trials found fewer deaths and cardiovascular events, and said selective outcome reporting warranted caution in low-risk people.

Are statins bad for your liver?

The label reports persistent liver enzyme increases above three times the upper limit in about 0.7 percent of patients in its clinical trials, and rare postmarketing reports of liver failure. A 2026 meta-analysis of double-blind trials confirmed abnormal liver function tests as causally associated with statins, and a systematic review of secondary-prevention trials found transaminase elevations were highest with atorvastatin. An enzyme rise is not the same as clinical liver injury, and the label says to consider liver enzyme testing before starting and when clinically indicated.

Do statins cause muscle pain?

Sometimes, and less often than patients report. In large blinded trials there was a small excess of muscle pain in year one, and only 1 in 15 muscle-pain reports was attributable to the statin. In clinical practice 15 to 20 percent of patients report muscle and joint effects against 1 to 5 percent in trials. In randomized rechallenge trials of people who had stopped a statin, intolerance was 36 percent on a statin and 26 percent on placebo. The label also warns about rhabdomyolysis and immune-mediated necrotizing myopathy, which a review describes as rare serious effects.

Do statins cause diabetes?

In an individual-participant meta-analysis of large trials, statin therapy increased new-onset diabetes by 10 to 36 percent, dose-dependently, predominantly in people whose blood sugar was already near the diagnostic threshold. A 2011 meta-analysis found a 13 percent higher risk in hypothesis-testing trials that was not significant once early observational data were included. The label says increases in HbA1c and fasting glucose have been reported.

Do statins cause dementia or memory loss?

The label lists rare reports of memory loss and confusion, generally nonserious and reversible when the statin was stopped. A 2026 systematic review found cholesterol-lowering drugs did not increase neurocognitive events or impair cognitive function, and an American Heart Association scientific statement judged that the evidence fails to support statins causing cognitive decline. Two case reports describe reversible deficits on simvastatin, which is why a person who notices a change should tell their prescriber.

Do statins deplete CoQ10?

In a meta-analysis of 12 randomized trials with 1,776 participants, statin treatment reduced circulating coenzyme Q10 regardless of statin type, intensity or duration. Whether the lower level causes symptoms is not shown: in 67 patients after a heart attack the 43 percent drop did not correlate with a muscle-injury marker. Supplement trials for statin muscle symptoms are mixed: a randomized crossover trial funded by the US National Institutes of Health found 600 mg a day of ubiquinol did not reduce muscle pain against placebo, and a meta-analysis of seven randomized trials funded by the Society for Applied Vitamin Research found a modest reduction.

Should I take a statin if my risk is low or my cholesterol is only borderline?

That is a decision for you and your prescriber, and the absolute numbers are what to ask for. The 2016 US Preventive Services Task Force recommendation covers adults aged 40 to 75 without prior cardiovascular events who have risk factors and a 10-year risk of 10 percent or greater, and a 2022 editorial describes the update as largely unchanged. Across 21 trials the absolute reductions were 0.8, 1.3 and 0.4 percentage points for death, heart attack and stroke. Ask what the absolute benefit is for you, who set the threshold, and what the label warns about.

Are statins banned in Europe?

No. England dispensed 78 million items of atorvastatin alone in 2025/26, the most of any drug, according to the NHS Business Services Authority.

What lowers LDL cholesterol in trials besides a prescription?

A systematic review found that soluble fiber interventions were associated with modest reductions in LDL cholesterol, with effects varying by fiber type and dose, and a meta-analysis of randomized trials found a clear dose-response relationship between psyllium fiber intake and LDL reductions. These are findings about food and fiber, not a replacement for a prescription; talk with your prescriber before changing treatment.